Question 1

What is the catalog number for EDG 7 (Endothelial Cell Differentiation Gene 7, LPA3, Lysophosphatidic Acid Receptor 3, edg-7) (MaxLight 490) discontinued?

Accepted Answer

The catalog number for EDG 7 (Endothelial Cell Differentiation Gene 7, LPA3, Lysophosphatidic Acid Receptor 3, edg-7) (MaxLight 490) discontinued is E2208-35-ML490.

Question 2

What sizes are available for EDG 7 (Endothelial Cell Differentiation Gene 7, LPA3, Lysophosphatidic Acid Receptor 3, edg-7) (MaxLight 490) discontinued?

Accepted Answer

EDG 7 (Endothelial Cell Differentiation Gene 7, LPA3, Lysophosphatidic Acid Receptor 3, edg-7) (MaxLight 490) discontinued is available in the following size(s): 100 µL.

Question 3

Is EDG 7 (Endothelial Cell Differentiation Gene 7, LPA3, Lysophosphatidic Acid Receptor 3, edg-7) (MaxLight 490) discontinued in stock?

Accepted Answer

EDG 7 (Endothelial Cell Differentiation Gene 7, LPA3, Lysophosphatidic Acid Receptor 3, edg-7) (MaxLight 490) discontinued

Selected Variant

E2208-35-ML490

Size: 100 µL

Product Specifications

Clonality

Pab

Question 4

Is this product tested for endotoxin levels?

Accepted Answer

Endotoxin testing status is noted on the datasheet where applicable, particularly for recombinant proteins intended for cell-based or functional assays. If this isn’t listed and you need confirmation, contact support with the catalogue number.

Question 5

Can I request additional validation data, such as western blot images, for this product?

Accepted Answer

Additional data may be available on request. Contact our technical support team with the catalogue number and we’ll check what supporting documentation the supplier can provide.

Question 6

What documentation should I request if this product is used for a regulated or intellectual-property-sensitive application?

Accepted Answer

If the product is subject to intellectual property protections, we’ll advise on any MTA or usage restrictions before shipping. Let us know your intended end use so we can confirm what’s required upfront.